Biofrontera Shares Resume Trade, Down ~30%
$BFRA
Biotechnology: Pharmaceutical Preparations
Health Care
Biofrontera Shares Resume Trade, Down ~30%
Save time and jump to the most important pieces.
EFFECT - Biofrontera AG (0001712641) (Filer)
15F-12B - Biofrontera AG (0001712641) (Filer)
POS AM - Biofrontera AG (0001712641) (Filer)
-Reuters
Gainers Revelation Biosciences (NASDAQ:REVB) stock increased by 29.9% to $2.0 during Wednesday's pre-market session. The market value of their outstanding shares is at $28.4 million. Biofrontera (NASDAQ:BFRA) shares rose 17.21% to $3.2. The market value of their outstanding shares is at $90.7 million. Mainz Biomed (NASDAQ:MYNZ) stock moved upwards by 14.19% to $15.45. The company's market cap stands at $212.2 million. Also check this: Tesla And 4 Other Stocks Sold By Insiders Hims & Hers Health (NYSE:HIMS) shares rose 12.61% to $4.73. The company's market cap stands at $969.6 million. As per the press release, Q4 earnings came out yesterday. NanoVibronix (NASDAQ:NAOV) shares incre
Gainers Biofrontera (NASDAQ:BFRA) stock moved upwards by 11.8% to $3.49 during Friday's pre-market session. The market value of their outstanding shares is at $98.9 million. Paratek Pharmaceuticals (NASDAQ:PRTK) stock rose 9.76% to $4.27. The market value of their outstanding shares is at $214.3 million. INmune Bio (NASDAQ:INMB) shares increased by 9.38% to $12.0. The market value of their outstanding shares is at $214.1 million. Revelation Biosciences (NASDAQ:REVB) stock rose 7.17% to $2.39. The company's market cap stands at $34.0 million. Black Diamond Therapeutic (NASDAQ:BDTX) stock moved upwards by 6.95% to $4.0. The market value of their outstanding shares is at $144.9 millio
3 - Biofrontera AG (0001712641) (Reporting)
Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, today reported its financial results for the nine months ended September 30, 2021. Key financial figures and business performance for the nine months ended September 30, 2021 In EUR thousands9M 20219M 2020ChangeQ3 2021Q3 2020ChangeRevenue18,473 20,829 (11)%5,379 4,713 14%thereof from product sales18,473 14,337 29%5,379 4,661 15%Gross profit on sales15,761 18,262 (14)%4,680 3,637 29%Research and development costs(4,516)(3,403)33%(1,595)(1,014)57%General and administrative costs(7,557)(6,882)10%(2,004)(2,410)19%S
Leverkusen, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, will be releasing its financial results for the first nine months ended September 30, 2021 on Wednesday, November 17, 2021. Conference calls for shareholders and interested investors will be held on Thursday, November 18, 2021, at the following times: In German, November 18, 2021 at 10:00 am CET (4:00 am ET)Dial-in number Germany: +49 69201744220Conference code: 35058739# In English, November 18, 2021 at 2:00 pm CET (8:00 am ET)Dial-in number USA: +1 8774230830Dial-in number UK: +44 2030092470Conference co
Leverkusen, Germany, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, will be releasing its financial results for the first six months ended June 30, 2021 on Thursday, August 19, 2021. Conference calls for shareholders and interested investors will be held on Friday, August 20, 2021, at the following times: In German, August 20, 2021 at 10:00 am CEST (4:00 am EST)Dial-in number Germany: +49 69201744220Conference code: 63828444# In English, August 20, 2021 at 2:00 pm CEST (8:00 am EST)Dial-in number USA: +1 8774230830Dial-in number UK: +44 2030092470Conference code: 78540812# Plea
Leverkusen, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera AG (the "Company") (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))), an international biopharmaceutical company, decided today its American Depositary Shares ("ADS") should be delisted from the Nasdaq Capital Market ("Nasdaq") and its reporting obligations with the Securities and Exchange Commission ("SEC") should be deregistered and terminated. The main purpose of the delisting is to reduce complexity in financial reporting and administrative costs. Biofrontera AG intends to maintain an amended ADS program on a Level I basis, which will allow investors to continue to hold their securities in the form of ADSs and trade the
Leverkusen, Germany, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (OTC:BFFTF) has been in mediation proceedings with Mr. Wilhelm K. T. Zours and Deutsche Balaton AG for a year in order to find a solution for the settlement of legal disputes and other differences (see ad hoc announcement of September 11, 2020). Mr. Zours is an indirect major shareholder of Biofrontera AG, holding the shares in Biofrontera AG through various companies (hereinafter "Deutsche Balaton Group"). Another major shareholder is Maruho Deutschland GmbH, a subsidiary of Maruho Co. Ltd, Japan. At the upcoming Annual General Meeting of Biofrontera AG on December 14, 2021
Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, today reported its financial results for the nine months ended September 30, 2021. Key financial figures and business performance for the nine months ended September 30, 2021 In EUR thousands9M 20219M 2020ChangeQ3 2021Q3 2020ChangeRevenue18,473 20,829 (11)%5,379 4,713 14%thereof from product sales18,473 14,337 29%5,379 4,661 15%Gross profit on sales15,761 18,262 (14)%4,680 3,637 29%Research and development costs(4,516)(3,403)33%(1,595)(1,014)57%General and administrative costs(7,557)(6,882)10%(2,004)(2,410)19%S
SC 13D/A - Biofrontera AG (0001712641) (Subject)
SC 13D/A - Biofrontera AG (0001712641) (Subject)
SC 13D/A - Biofrontera AG (0001712641) (Subject)